Gynecologic Oncology | Interview with Robert Coleman, MD

published 2 months ago by Dr Neil Love

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Coleman on the following topics: Clinical implications of the Phase III VELIA study assessing veliparib in combination with carboplatin/paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC (00:00) Homologous recombination deficiency testing and implications for treatment decision-making in newly diagnosed advanced OC (4:11) Risks with combining PARP inhibitor therapy and chemotherapy for advanced OC; optimizing the use of chemotherapy, bevacizumab and a PARP inhibitor in the front-line setting (7:19) CME information and select publications

more episodes from Research To Practice | Oncology Videos